quinazolines has been researched along with Inflammatory Breast Cancer in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, S; Li, Y; Liu, Q; Liu, Y; Qi, M; Shao, L; Zhang, J | 1 |
| Aldrich, AJ; Allensworth, JL; Devi, GR; Ingram, SM; Sexton, JZ; Smith, GR; Williams, KP | 1 |
| Bessonov, AA; Bozhok, AA; Manikhas, AG; Nikolaev, KS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Ali, SM; Alpaugh, RK; Buell, JK; Cristofanilli, M; Hiemstra, CN; Lipson, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Wu, H; Yu, JQ | 1 |
| Ali, SM; Alpaugh, RK; Buell, JK; Cristofanilli, M; Downing, SR; Lipson, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Wu, H; Yu, JQ | 1 |
| Cristofanilli, M; Dong, X; Fernandez, SV; Foster, E; Klinowska, T; Mu, Z; Womack, C | 1 |
| Bertucci, F; Gonçalves, A; Monneur, A; Viens, P | 1 |
| Cristofanilli, M; Dawood, S | 1 |
| Kumar, PV; Prabaharan, S; Ravind, R | 1 |
| Afrit, M; Ahmed, SB; Arpornwirat, W; Chitapanarux, I; Dechaphunkul, A; Ganju, V; Gibson, N; Goh, G; Guiver, K; Herrero, J; Im, SA; Johnston, SR; Kim, SB; Maneechavakajorn, J; Schmid, R; Spector, N; Swanton, C; Uttenreuther-Fischer, M; Yau, T | 1 |
| Aird, KM; Allensworth, JL; Batinic-Haberle, I; Devi, GR; Dewhirst, MW; Lyerly, HK | 1 |
| Crane, K | 1 |
| Bartlett, J; Bogaerts, J; Bonnefoi, H; Cameron, D; Debled, M; Fiche, M; Fournier, M; Koch, KM; Marreaud, S; Nobahar, M; Pierga, JY; Zaman, K; Zimmer, A | 1 |
| Alvarez, RH; Blackwell, KL; Cristofanilli, M; Gladkov, O; Gomez, HL; Johnston, SR; Manikhas, A; Ranganathan, S; Redhu, S; Rubin, SD; Safina, S; Shao, Z; Trudeau, ME | 1 |
2 review(s) available for quinazolines and Inflammatory Breast Cancer
| Article | Year |
|---|---|
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Non-Small-Cell Lung; Exanthema; Humans; Incidence; Inflammatory Breast Neoplasms; Neoplasm Staging; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index | 2017 |
[Systemic treatments of inflammatory breast cancer: an overview].
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Trastuzumab | 2014 |
4 trial(s) available for quinazolines and Inflammatory Breast Cancer
| Article | Year |
|---|---|
[HER2-positive breast cancer: standard and double targeted therapy].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
Topics: Adolescent; Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine; Young Adult | 2016 |
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids | 2013 |
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Female; Humans; Indazoles; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
8 other study(ies) available for quinazolines and Inflammatory Breast Cancer
| Article | Year |
|---|---|
Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; High-Throughput Screening Assays; Humans; Inflammatory Breast Neoplasms; Lapatinib; Quinazolines; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2014 |
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Female; Gene Amplification; Humans; Inflammatory Breast Neoplasms; Mice; Mice, SCID; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model.
Topics: Afatinib; Antibodies, Monoclonal; Bevacizumab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Inflammatory Breast Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Outcome Assessment, Health Care; Panitumumab; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Remission Induction; Survival Analysis; Trastuzumab | 2015 |
Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Prognosis; Quinazolines | 2016 |
ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.
Topics: Antioxidants; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glutathione; Humans; Inflammatory Breast Neoplasms; Membrane Potential, Mitochondrial; Oxidative Stress; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Sulfones; Superoxide Dismutase | 2012 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |